Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation

Some concerns remain about the safety of nintedanib in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD), such as in the presence of comorbidities or in combination with biologic, targeted synthetic, and/or conventional synthetic disease-modifying antirheumatic drugs (DMA...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of rheumatology Ročník 52; číslo 5; s. 420
Hlavní autori:	Sebastiani, Marco, Lepri, Gemma, Iannone, Claudia, Cassione, Emanuele Bozzalla, Guggino, Giuliana, Lo Monaco, Andrea, Foti, Roberta, Fornaro, Marco, Chimenti, Maria Sole, Fassio, Angelo, Truglia, Simona, Cozzini, Francesca, Carletto, Antonio, Giollo, Alessandro, Corrado, Addolorata, Bazzani, Chiara, Guiducci, Serena, Favalli, Ennio, Bugatti, Serena, Iannone, Florenzo, Caporali, Roberto, Manfredi, Andreina
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada 01.05.2025
Predmet:	Aged Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Comorbidity Drug Therapy, Combination Female Humans Indoles - adverse effects Indoles - therapeutic use Italy Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Male Middle Aged Registries Retrospective Studies Treatment Outcome Italy combination therapy nintedanib comorbidity interstitial lung disease rheumatoid arthritis safety
ISSN:	1499-2752, 1499-2752
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!